i. It delays the introduction on the product. not simply will it choose a long time to finish clinical assessments, but after they are submitted the maker will have to await completion of any supplementary tests the Administration decides to make and the sluggish unwinding of its bureau­cratic pink tape, which happens to be further more delayed by